What is the 13F Pro Quality Score for VTVT?

13F Pro ranks vTv Therapeutics Inc. (VTVT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VTVT's current score at https://13fpro.ai/research/VTVT (free sign-up required for the full ranking).

Which hedge funds own the most VTVT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VTVT include Samsara BioCapital,, FMR, MILLENNIUM MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/VTVT as soon as new 13F filings post.

Where does 13F Pro source VTVT data?

All vTv Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. vTv Therapeutics Inc. files with the SEC under CIK 1641489. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VTVT in?

vTv Therapeutics Inc. (VTVT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VTVT research updated on 13F Pro?

VTVT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

vTv Therapeutics Inc.(VTVT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1641489 VTVT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $12.4M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

VTVT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for vTv Therapeutics Inc. (VTVT), a Healthcare sector company. VTVT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $12.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), vTv Therapeutics Inc. reports quarterly revenue of $36.8M, net income of $24.1M, free cash flow of $9.2M. Top institutional holders of VTVT by reported 13-F value include Samsara BioCapital,, FMR, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. VTVT trades on the Nasdaq exchange and files with the SEC under CIK 1641489. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTVT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for vTv Therapeutics Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$36.8M

Net Income

Q1 2026

$24.1M

Free Cash Flow

Q1 2026

$9.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2025

FY22 $2.0MFY23 $0.00FY24 $1.0MFY25 $0.00

Net Income

-46.1% YoY

$-27.0MFY 2025

FY22 $-19.2MFY23 $-20.3MFY24 $-18.5MFY25 $-27.0M

Operating Income

-35.7% YoY

$-32.8MFY 2025

FY22 $-22.5MFY23 $-25.5MFY24 $-24.2MFY25 $-32.8M

Total Assets

+134.9% YoY

$89.9MFY 2025

FY22 $33.2MFY23 $11.0MFY24 $38.3MFY25 $89.9M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+0.2% YoY

$-25.3MFY 2025

FY22 $-16.0MFY23 $-19.1MFY24 $-25.3MFY25 $-25.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019	FY 2018
Revenue	$0.00 -100.0%	$1.0M	$0.00 -100.0%	$2.0M -27.0%	$2.8M -77.8%	$12.4M
Net Income	$-27.0M -46.1%	$-18.5M +8.8%	$-20.3M -5.7%	$-19.2M -46.9%	$-13.0M -64.9%	$-7.9M
Operating Income	$-32.8M -35.7%	$-24.2M +5.2%	$-25.5M -13.1%	$-22.5M -7.9%	$-20.9M -5.4%	$-19.8M
Total Assets	$89.9M +134.9%	$38.3M +247.3%	$11.0M -66.9%	$33.2M +258.7%	$9.3M +8.3%	$8.6M
Total Debt	—	—	—	—	$5.2M -66.2%	$15.3M
Operating Cash Flow	$-25.3M +0.2%	$-25.3M -32.6%	$-19.1M -19.1%	$-16.0M +30.4%	$-23.0M +14.3%	$-26.9M

AI Insight: VTVT Financial Trends

vTv swung to $37M revenue and $24M net income in Q1 2026 after three years of losses and zero sales.

• Revenue jumped from $0M to $37M in Q1 2026; net income turned positive at $24M versus $9M loss in Q3 2025.

• Operating income improved to $23M in Q1 2026 from negative $11M in Q3 2025; operating cash flow positive at $9M.

• Equity strengthened to $90M in Q1 2026 from $3M nadir in Q2 2025, likely driven by capital raise or asset sale.

⚠ Validate sustainability of $37M quarterly revenue and $24M profitability — appears to be inflection, not recurring run rate.

⚠ Operating cash flow ($9M) lags net income ($24M) by $15M in Q1 2026 — monitor working capital and accrual quality.

AI Insight: VTVT Ratio Trends

vTv swung from severe losses across 2024–2025 to massive profitability in Q1 2026, with OpMargin and NPM both exceeding 60%.

• Operating margin jumped from negative in TTM to 63.1% in Q1 2026; net profit margin surged to 65.5%.

• ROE and ROA reversed sharply: ROE from -49.3% in Q3 2025 to 107.3% in Q1 2026; ROA from -35.0% to 97.7%.

• ROIC improved from -60.7% in Q3 2025 to -48.9% in Q4 2025, though TTM ROIC remains negative at -3.4%.

⚠ Extreme Q1 2026 profitability metrics may reflect one-time items or seasonality; TTM lags suggest 2024–2025 losses still dominating annual results.

⚠ ROIC data missing for Q1 2026; confirm whether Q1 improvement is sustainable or driven by accounting adjustments.

Get alerted when VTVT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for vTv Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VTVT

Samsara BioCapital, LLC
$11.8M298,496 sh
FMR LLC
$10.3M260,391 sh
MILLENNIUM MANAGEMENT LLC
$8.2M206,288 sh
Siren, L.L.C.
$6.5M163,000 sh
BAKER BROS. ADVISORS LP
$5.9M148,314 sh
Trails Edge Capital Partners, LP
$5.5M139,578 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.3M108,922 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.3M32,886 sh
NORTHERN TRUST CORP
$715.9K18,052 sh
VANGUARD FIDUCIARY TRUST CO
$639.6K16,126 sh

Fund	Value	Shares
Samsara BioCapital, LLC	$11.8M	298,496
FMR LLC	$10.3M	260,391
MILLENNIUM MANAGEMENT LLC	$8.2M	206,288
Siren, L.L.C.	$6.5M	163,000
BAKER BROS. ADVISORS LP	$5.9M	148,314
Trails Edge Capital Partners, LP	$5.5M	139,578
VANGUARD CAPITAL MANAGEMENT LLC	$4.3M	108,922
GEODE CAPITAL MANAGEMENT, LLC	$1.3M	32,886
NORTHERN TRUST CORP	$715.9K	18,052
VANGUARD FIDUCIARY TRUST CO	$639.6K	16,126

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VTVT on your watchlist

Track score changes the day vTv Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VTVT a good stock to buy?

13F Pro's AI-powered analysis of vTv Therapeutics Inc. (VTVT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VTVT are available on the VTVT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VTVT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VTVT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of vTv Therapeutics Inc.'s investment landscape.